Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.

ABSTRACT:

Importance

Although it has been reported that osimertinib mesylate provides better survival benefits compared with first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), it remains unclear whether osimertinib is associated with more cancer therapy-related cardiac events (CTRCEs) compared with other EGFR TKIs, as does the extent of the association these adverse effects may have with overall survival. This issue is particularly critical due to the high prevalence of EGFR variants within Asian populations, including that of Taiwan.

Objective

To compare CTRCEs and their association with survival in patients treated with osimertinib vs other EGFR TKIs.

Design, setting, and participants

This cohort study was conducted at the Nat

SUBMITTER: Lin CY 

PROVIDER: S-EPMC11621985 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature